Hologic, Inc. $HOLX Shares Sold by Aware Super Pty Ltd as trustee of Aware Super

Key Points

• Aware Super Pty Ltd significantly reduced its holdings in Hologic, Inc. by 68.0% during the second quarter, owning 3,259 shares worth approximately $212,000 after selling 6,925 shares.
• Hologic reported earnings of $1.08 per share for the last quarter, surpassing analysts' expectations of $1.05, with revenue of $1.02 billion, slightly above projections.
• Several analysts have upgraded Hologic's stock rating recently, including raising the target price from $72 to $87, indicating a bullish outlook.

Aware Super Pty Ltd as trustee of Aware Super decreased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 68.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,259 shares of the medical equipment provider's stock after selling 6,925 shares during the period. Aware Super Pty Ltd as trustee of Aware Super's holdings in Hologic were worth $212,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Bridges Investment Management Inc. raised its holdings in Hologic by 15.6% in the 2nd quarter. Bridges Investment Management Inc. now owns 26,847 shares of the medical equipment provider's stock valued at $1,749,000 after acquiring an additional 3,620 shares during the last quarter. TD Asset Management Inc raised its holdings in Hologic by 1.4% in the 2nd quarter. TD Asset Management Inc now owns 1,530,317 shares of the medical equipment provider's stock valued at $99,715,000 after acquiring an additional 21,005 shares during the last quarter. Morningstar Investment Management LLC acquired a new stake in Hologic in the 2nd quarter valued at about $357,000. Sequoia Financial Advisors LLC raised its holdings in Hologic by 80.6% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 11,342 shares of the medical equipment provider's stock valued at $739,000 after acquiring an additional 5,063 shares during the last quarter. Finally, Yousif Capital Management LLC grew its stake in shares of Hologic by 2.1% in the 2nd quarter. Yousif Capital Management LLC now owns 49,095 shares of the medical equipment provider's stock valued at $3,199,000 after buying an additional 1,029 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $68.50 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The stock has a market capitalization of $15.24 billion, a P/E ratio of 28.42, a PEG ratio of 2.30 and a beta of 0.63. The company has a 50 day moving average price of $67.08 and a 200 day moving average price of $63.45. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the company posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 1.88% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and increased their price target for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Mizuho set a $75.00 price target on shares of Hologic in a research note on Thursday, July 31st. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Wednesday, October 1st. Finally, Argus increased their price target on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research note on Friday, September 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $80.15.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.